Uncovering the Pharmacological Mechanism of 2-Dodecyl-6-Methoxycyclohexa-2,5 -Diene-1,4-Dione Against Lung Cancer Based on Network Pharmacology and Experimental Evaluation

Wang, Lihui; Yang, Xin; Song, Qiong; Fu, Jiejun; Wang, Wenchu; Du, Kechen; Chen, Shuai; Cao, Jinjin; Huang, Renbin; Zou, Chunlin

doi:10.3389/fphar.2021.617555

Cited by 7 publications

(5 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…During article searching, two essays [ 14 , 15 ] regarding to lung adenocarcinoma (LAUD) and lung squamous cell carcinoma (LUSC) were from the same database as an included article [ 15 ] on lung cancer (LC). In order to prevent repeated inclusion of data, we have deleted the above two essays.…”

Section: Methodsmentioning

confidence: 99%

Prognostic role of E2F1 gene expression in human cancer: a meta-analysis

Li,

Bi,

et al. 2023

BMC Cancer

View full text Add to dashboard Cite

Objective E2F1 has been confirmed to be highly expressed in a variety of cancers. To better understand the prognostic value of E2F1 in cancer patients, this study was conducted to comprehensively evaluate the prognostic value of E2F1 in cancer according to published data. Method PubMed, Web of Science and CNKI database were searched until May 31th, 2022 by using key words to retrieve the published essays on the role of E2F1 expression in the prognostic value of cancer. The essays were identified according to the inclusion and exclusion criteria. The pooled result of hazard ratio and 95% confidence interval was calculated with Stata17.0 software. Result A total of 17 articles were included in this study involved in 4481 cancer patients. The pooled results showed that higher E2F1 expression was significantly correlated with unfavorable overall survival (HR = 1.10, I2 = 95.3%, *PHeterogeneity = 0.000) and disease-free survival (HR = 1.41, I2 = 95.2%, *PHeterogeneity = 0.000) of cancer patients. Such a significant association of was maintained subgroup of sample size of patients (> 150: for OS, HR = 1.77, and for DFS, HR = 0.91; or < 150: for OS, HR = 1.93, and for DFS, HR = 4.39), ethnicity (Asian: for OS, HR = 1.65, and for DFS, HR = 1.08; or not Asian: HR = 3.55, and for DFS, HR = 2.87), the data from database (clinical: for OS, HR = 1.24, and for DFS, HR = 1.40; or database: for OS, HR = 2.29, and for DFS, HR = 3.09), paper published year (after 2014: for OS, HR = 1.90;and for DFS,HR = 1.87; or before 2014: for OS, HR = 1.40, and for DFS, HR = 1.22); cancer type (female specific cancer: for OS, HR = 1.41, and for DFS, HR = 0.64; or non-gender specific cancers: for OS, HR = 2.00, and for DFS, HR = 2.95). In addition, according to the database data, we also found that higher E2F1 expression level would lead to worse prognosis of patients, and the results were consistent with the statistical analysis results in the paper. Conclusion E2F1 could be served as a prognostic biomarker in cancer patients and higher levels of in cancer patients could predict shorter overall survival and disease-free survival.

show abstract

Section: Methodsmentioning

confidence: 99%

Prognostic role of E2F1 gene expression in human cancer: a meta-analysis

Li,

Bi,

et al. 2023

BMC Cancer

View full text Add to dashboard Cite

show abstract

“…Previous studies reported that DMDD exhibited anti-tumor effects against BC in mice (8)(9)(10)(11). In addition, DMDD can block tumorigenesis through modulation of the cell cycle in lung cancer (12). However, DMDD has poor solubility in water, thus limiting its application as an antitumor agent.…”

Section: Original Articlementioning

confidence: 99%

Biomimetic cytomembrane-coated ZIF-8-loaded DMDD nanoparticle and sonodynamic co-therapy for cancer

Zhao¹,

Chen²,

Zhu³

et al. 2022

Ann Transl Med

View full text Add to dashboard Cite

Background: Breast cancer (BC) is the most common type of cancer affecting females. It is also a leading cause of cancer-related death in women worldwide.Methods: Sonodynamic therapy (SDT) is an emerging therapeutic strategy for cancer treatment. SDT ensures non-invasive penetration of deep tumors and results in activation of non-toxic sonosensitizers administered in deep tumor sites to become cytotoxic. It has been reported that 2-dodecyl-6methoxycyclohexa-2,5-diene-1,4-dione (DMDD) has a significant anti-tumor effect against various cancer types including BC. However, DMDD is hydrophobic. Therefore, a one-step encapsulation method was used in the current study to construct zeolitic imidazole frameworks-8 (ZIF-8) loaded with DMDD and sonosensitizer chlorin e6 (Ce6). ZIF-8 was further modified by coating it with a biomimetic cell membrane to improve targeted delivery.Results: In vitro and in vivo results indicated that the nanomedicines had great biocompatibility properties and targeting ability. The nanocomposite exhibited a higher release rate under an acidic tumor microenvironment. The tumor killing effect of reactive oxygen species (ROS) generated from Ce6 and inhibition of tumor growth was enhanced after ultrasound (US) treatment, which might be caused by the increase in apoptosis rate.Conclusions: These findings show that the combination of nanomedicine and SDT provides a potential therapeutic method for BC.

show abstract

“…During article searching, two literatures [13,14] regarding to lung adenocarcinoma (LAUD) and lung squamous cell carcinoma (LUSC) were from the same database as an included article [14] on lung cancer (LC). In order to prevent repeated inclusion of data, we have deleted the above two literatures.…”

Section: Data Extraction and Checkingmentioning

confidence: 99%

Prognosis Role of E2F1 in Cancer: a Meta-analysis

Wen

Liu

et al. 2022

Preprint

View full text Add to dashboard Cite

Objective E2F1 has been confirmed to be highly expressed in a variety of cancers. To better understand the prognostic value of E2F1 in cancer patients, this study was conducted to comprehensively evaluate the prognostic value of E2F1 in cancer according to published data. Method PubMed, Web of Science and CNKI Database were searched until May 31th, 2022 by using key words to retrieve the published literatures on the role of E2F1 expression in the prognostic value of cancer. The literatures were identified according to the inclusion and exclusion criteria. The pooled result of hazard ratio (HR) and 95% confidence interval (CI) was calculated with Stata17.0 software. Result A total of 17 articles were included in this study involved in 4481 cancer patients. The pooled results showed that higher E2F1 expression was significantly correlated with unfavorable overall survival (OS) (HR = 1.10, 95%CI:1.03–1.16, I2 = 95.3%, PHeterogeneity=0.000) and disease-free survival (DFS) (HR = 1.41, 95%CI:1.33–1.49, I2 = 95.2%, PHeterogeneity=0.000) of cancer patients. Such a significant association of was maintained subgroup of sample size of patients (> 150: for OS, HR = 1.77, 95%CI:1.25–2.51, and for DFS, HR = 0.91, 95%CI:0.28–2.98; or < 150: for OS, HR = 1.93, 95%CI:0.94–3.06, and for DFS, HR = 4.39, 95%CI:4.05–4.76), ethnicity (Asian: for OS, HR = 1.65, 95%CI:1.19–2.29, and for DFS, HR = 1.08, 95%CI:0.25–4.61; or not Asian: HR = 3.55, 95%CI:1.92–6.55, and for DFS, HR = 2.87, 95%CI:1.15–7.14), the data from database (clinical: for OS, HR = 1.24, 95%CI: 0.54–2.82, and for DFS, HR = 1.40, 95%CI:0.40–4.94; or database: for OS, HR = 2.29, 95%CI:1.72–3.06, and for DFS, HR = 3.09, 95%CI:1.12–8.49), paper published year (after 2014: for OS, HR = 1.90, 95%CI:1.41–2.55;and for DFS,HR = 1.87, 95%CI:1.21–2.89; or before 2014: for OS, HR = 1.40, 95%CI:0.27–7.13, and for DFS, HR = 1.22, 95%CI:0.10-15.59);cancer type (female specific cancer: for OS, HR = 1.41, 95%CI:0.43–4.65, and for DFS, HR = 0.64, 95%CI:0.15–2.72; or non-gender specific cancers: for OS, HR = 2.00, 95%CI:1.30–3.09, and for DFS, HR = 2.95, 95%CI:1.47–5.91). Conclusion E2F1 could be served as a prognostic biomarker in cancer patients and higher levels of in cancer patients could predict shorter OS and DFS.

show abstract

Uncovering the Pharmacological Mechanism of 2-Dodecyl-6-Methoxycyclohexa-2,5 -Diene-1,4-Dione Against Lung Cancer Based on Network Pharmacology and Experimental Evaluation

Cited by 7 publications

References 51 publications

Prognostic role of E2F1 gene expression in human cancer: a meta-analysis

Prognostic role of E2F1 gene expression in human cancer: a meta-analysis

Biomimetic cytomembrane-coated ZIF-8-loaded DMDD nanoparticle and sonodynamic co-therapy for cancer

Prognosis Role of E2F1 in Cancer: a Meta-analysis

Contact Info

Product

Resources

About